NEWS RELEASE

Teijin and JCR Cease JTR-161 Dental Pulp Stem Cell Research
Tokyo, Japan, April 18, 2022 ---Teijin Limited (Teijin) and JCR Pharmaceuticals Co., Ltd.
(JCR) announced today that they have decided to terminate their co-development andJapan licensing agreement aimed at developing JTR-161, an allogeneic regenerative
medical product containing dental pulp stem cells (DPCs) for the intended purpose ofhelping patients recover from acute cerebral infarctions (strokes). Using DPC isolated
from human teeth extraction bodies, JTR-161 was expected to effectively suppressinflammation through immune regulatory factors and stimulate organ regeneration
through trophic factors.
JCR and Teijin signed their agreement in July 2017 and launched Japan-based Phase
I/II clinical trials in 2019 to examine the safety and efficacy of intravenously administering
JTR-161 to patients who have suffered acute cerebral infarction. The primary endpoint
was not achieved, however, so the two companies have decided to terminate theiragreement and cease joint development And Teijin will return its Japan rights to JCR.
JCR works to develop proprietary technologies and innovative products in anticipation of
the needs of the times under our corporate philosophy of "Contributing towards people’s
healthcare through pharmaceutical products.” JCR, as a specialty pharma in the raredisease arena, is fully committed to tackling ambitious initiatives in service of its patientsworldwide.
Teijin’s healthcare business is focused on enhancing the quality of human life to enablepeople worldwide to enjoy fulfilling lives from birth to their final days. Teijin actively
pursues alliances to research and develop medical products that enable patients tobenefit from innovative and effective treatments.
About JCR Pharmaceuticals
JCR is a biopharmaceutical specialty pharma which is engaged in research,development, manufacture, and market of pharmaceuticals based on regenerative
medicine, genetic recombination, and gene therapy technologies that have pioneered
the era under our corporate philosophy of "Contributing towards people’s healthcare
through pharmaceutical products.” In the arena of rare diseases, which has been JCR’s
target since its establishment in 1975, JCR has been working on proprietary technology
developments and creation of products in a manner to be “one step ahead” ofcompetitors at all times. JCR aims to create sustainable values for patients with variousdiseases. Our core values – reliability, confidence, and persistence – benefit all ourstakeholders, including employees, partners, and patients. Together we soar.
For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jcrpharm.co.jp
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursingcare and pre-symptomatic healthcare; and IT including B2B solutions for medical,corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions,” Teijin aims to be a company that
supports the society of the future. The group comprises more than 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 836.5 billion (USD 7.7 billion) and total assets of JPY 1,036.4 billion (USD9.5 billion) in the fiscal year that ended on March 31, 2021.
Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp